PURPOSE Women with Personal History of Breast Cancer (PHBC) face a higher risk of recurrence or new primary disease. The aim of this study was to present the results of the 'COMBO TRIAL,' a prospective intra-individual study evaluating the performance of Contrast- Enhanced Mammography (CEM) compared with Digital Mammography (DM) in the surveillance of women with PHBC. MATERIAL AND METHODS Between January 2023 and February 2025, 1551 asymptomatic women who underwent breast-conserving surgery ...
Interleukin-1 receptor 8 (IL-1R8) is an atypical Interleukin-1 receptor (ILR) family member that mitigates inflammatory responses by dampening ILR and Toll-like receptor (TLR) signaling. Studies conducted on IL-1R8-deficient NK cells established its key role as immune checkpoint and negative regulator of IL-18-dependent activation. In particular, IL-1R8-deficiency unleashes NK cell-mediated immune surveillance against hematogenous metastasis, liver cancer and viral dissemination. However, the...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Although the complement system has long been considered a component of immune surveillance, accumulating evidence indicates its pro-tumoral role in several cancer types. In this thesis, we explored the contribution of complement activation to PDAC progression using preclinical pancreatic tumor models and animals deficient for C3-upstream (C1q-/-, C4-/-, MBL1/2-/-, fB-...
Il cancro al colon (CRC) comprende una famiglia complessa di tumori diversi per morfologia, infiltrazione del sistema immunitario, risposta ai farmaci e mutazioni genetiche, tra cui APC/KRAS/TP53/SMAD4. Le mutazioni nell'oncogene KRAS, soprattutto ai codoni 12 e 13, sono associate all'inizio e alla progressione del CRC, ma mancano in clinica di trattamenti bersaglio-specifici. Gli organoidi derivanti da pazienti (PDOs) sono stati dimostrati una nuova tecnologia di modello in vitro 3D utilizza...
Diffuse Large B-cell Lymphoma (DLBCL) represents the most common subtype of aggressive Non-Hodking Lymphoma (NHL). Bispecific antibodies (BsAbs) such as Glofitamab, have expanded therapeutic options for relapsed/refractory (R/R) DLBCL, including patients failing CAR-T. Despite high response rates, resistance and relapse remain major challenges, and current prognostic tools fail to accurately stratify patients and capture disease heterogeneity. In this context, circulating tumor DNA (ctDNA) an...